NCT06604533 Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer
| NCT ID | NCT06604533 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Australasian Gastro-Intestinal Trials Group |
| Condition | Abdominal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-07 |
| Primary Completion | 2030-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Patients with diagnosis of oligometastatic disease from primary colorectal, upper gastrointestinal (e.g. gastric, oesophagus, pancreatic), breast, non-small cell lung, renal cell, or gynaecological malignancy. Oligometastatic disease with controlled primary disease\* and maximum total of 5 metastatic lesions in a maximum of 2 different organ systems in any of the following sites: 1. Liver 2. Adrenal 3. Abdomino-pelvic lymph node 4. Other abdominal site e.g. pancreatic, renal. 5. Other pelvic site 6. Bony or lung is allowed only if in conjunction with an abdominal site above * De novo or metachronous oligometastatic disease where the original tumour site has been treated with curative intent. * Controlled primary disease in metachronous oligometastastic disease defined as at least 3 months since original tumour treated with curative intent and no progression at primary site * Controlled primary disease in de novo oligometastatic disease def
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.